Faculty

Back to Index
Paul S. Gaynon, MD
Professor of Pediatrics
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 2163

Publications

A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia. Cancer Genet. 2017 Oct; 216-217:91-99. View in: PubMed

Mercaptopurine in childhood acute lymphoblastic leukaemia. Lancet Oncol. 2017 Apr; 18(4):425-426. View in: PubMed

Historical Controls? Haematologica. Historical Controls? Haematologica. 2017 Mar; 102(3):e117. View in: PubMed

Mercaptopurine in childhood acute lymphoblastic leukaemia. Lancet Oncol. 2017 Feb 28. View in: PubMed

"The Second Time is Sweeter After All". Br J Haematol. 2017 Feb; 176(4):511-512. View in: PubMed

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View in: PubMed

Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 Jul; 38(5):345-9. View in: PubMed

Oligoclonality and new agent evaluation in acute lymphoblastic leukaemia. Br J Haematol. 2016 Jun; 173(6):950-7. View in: PubMed

Reply: T-Cell Acute Lymphoblastic Leukemia, Minimal Residual Disease, and Lymphocyte Recovery. Pediatr Blood Cancer. 2016 May; 63(5):945. View in: PubMed

Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. Pediatr Blood Cancer. 2016 Feb; 63(2):255-61. View in: PubMed

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 2015 Dec 1; 121(23):4205-11. View in: PubMed

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Cancer. 2015 Dec 01; 121(23):4205-11. View in: PubMed

Comparative Toxicity by Sex Among Children Treated for Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2015 Dec; 62(12):2140-9. View in: PubMed

End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 Nov; 62(11):2040-3. View in: PubMed

ALL and osteonecrosis. Blood. 2015 Oct 8; 126(15):1734-5. View in: PubMed

ALL and osteonecrosis. Blood. 2015 Oct 08; 126(15):1734-5. View in: PubMed

Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group. J Immunother. 2015 Sep; 38(7):299-305. View in: PubMed

Improving access to novel agents for childhood leukemia. Cancer. 2015 Jun 15; 121(12):1927-36. View in: PubMed

Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (=200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. Br J Haematol. 2015 Feb; 168(4):533-46. View in: PubMed

A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014 Aug; 36(6):458-63. View in: PubMed

CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. Integr Biol (Camb). 2014 Aug; 6(8):766-80. View in: PubMed

CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. Integr Biol (Camb). 2014 Jul 21; 6(8):766-80. View in: PubMed

Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2014 May 1; 32(13):1331-7. View in: PubMed

Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol. 2014 May 01; 32(13):1331-7. View in: PubMed

High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemia. Front Pediatr. 2014; 2:96. View in: PubMed

Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol. 2013 Dec; 25 Suppl 3:S1-13; quiz S14-6. View in: PubMed

Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol. 2013 Dec; 25 Suppl 3:S1-S13. View in: PubMed

Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant. Fetal Pediatr Pathol. 2013 Jun; 32(3):175-83. View in: PubMed

Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood. 2013 May 23; 121(21):4348-54. View in: PubMed

Once upon a time--a personal view on episodes in leukemia research in Germany, and beyond. Klin Padiatr. 2013 May; 225 Suppl 1:S5. View in: PubMed

Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS One. 2013; 8(11):e80732. View in: PubMed

Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer. 2012 Oct; 59(4):765. View in: PubMed

ABT-751 in relapsed childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Oct; 34(7):583-4. View in: PubMed

Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012 Sep; 13(9):906-15. View in: PubMed

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012 Jul 12; 120(2):285-90. View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant. 2012 Jul; 18(7):979-81. View in: PubMed

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012 May 10; 30(14):1663-9. View in: PubMed

Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12; 366(15):1371-81. View in: PubMed

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012 Apr; 18(4):505-22. View in: PubMed

CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2012 Jan; 156(1):89-98. View in: PubMed

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 01; 118(23):6043-9. View in: PubMed

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 1; 118(23):6043-9. View in: PubMed

A remembrance: James B. Nachman 1948-2011. Pediatr Blood Cancer. 2011 Oct; 57(4):533-4. View in: PubMed

James B. Nachman, 1948 to 2011: a remembrance. J Pediatr Hematol Oncol. 2011 Aug; 33(6):403-5. View in: PubMed

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Jul 14; 118(2):243-51. View in: PubMed

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90. View in: PubMed

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood. 2011 Mar 17; 117(11):3010-5. View in: PubMed

Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer. 2010 Sep; 55(3):421-9. View in: PubMed

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug; 55(2):254-9. View in: PubMed

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. View in: PubMed

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 1; 54(7):872-8. View in: PubMed

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 08; 115(14):2740-8. View in: PubMed

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 8; 115(14):2740-8. View in: PubMed

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010 Feb 01; 28(4):648-54. View in: PubMed

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010 Feb 1; 28(4):648-54. View in: PubMed

Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010 Feb; 24(2):285-97. View in: PubMed

Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol. 2009 Dec; 31(12):920-6. View in: PubMed

A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64. View in: PubMed

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 01; 27(31):5189-94. View in: PubMed

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009 Nov 01; 27(31):5175-81. View in: PubMed

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 1; 27(31):5189-94. View in: PubMed

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009 Nov 1; 27(31):5175-81. View in: PubMed

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7. View in: PubMed

An adjustment for patient heterogeneity in the design of two-stage phase II trials. Stat Med. 2009 Sep 10; 28(20):2566-79. View in: PubMed

Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep. 2008 Nov; 10(6):453-8. View in: PubMed

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 1; 112(5):1646-54. View in: PubMed

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 01; 112(5):1646-54. View in: PubMed

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol. 2008 Aug 20; 26(24):3971-8. View in: PubMed

Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2008 Jun; 49(6):1142-54. View in: PubMed

Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008 Apr; 4(2):327-36. View in: PubMed

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 01; 111(5):2548-55. View in: PubMed

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008 Mar 1; 111(5):2548-55. View in: PubMed

Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007 Dec 20; 25(36):5800-7. View in: PubMed

Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007 Jul; 46(7):684-93. View in: PubMed

Treatment of pediatric acute lymphoblastic leukemia: progress achieved and challenges remaining. Curr Hematol Malig Rep. 2007 Jul; 2(3):193-201. View in: PubMed

Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20; 25(15):2063-9. View in: PubMed

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 1; 109(3):926-35. View in: PubMed

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 01; 109(3):926-35. View in: PubMed

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006 Aug 15; 108(4):1165-73. View in: PubMed

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006 Aug; 47(2):141-6. View in: PubMed

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol. 2006 Jul 1; 24(19):3150-6. View in: PubMed

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol. 2006 Jul 01; 24(19):3150-6. View in: PubMed

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23. View in: PubMed

Treatment adherence and 6-mercaptopurine metabolites. Pediatr Blood Cancer. 2006 Feb; 46(2):120-1. View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006 Jan; 12(1):1-30. View in: PubMed

Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005 Dec 15; 106(13):4043-9. View in: PubMed

Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005 Dec; 131(5):579-87. View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2005 Nov; 11(11):823-61. View in: PubMed

The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia. 2005 Jul; 19(7):1145-52. View in: PubMed

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82. View in: PubMed

Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005 Jan; 44(1):21-8. View in: PubMed

Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. View in: PubMed

Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004 Aug; 43(2):103-4. View in: PubMed

Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia. 2004 Jun; 18(6):1043-53. View in: PubMed

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004 Apr; 26(4):217-26. View in: PubMed

RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia. 2004 Apr; 18(4):685-92. View in: PubMed

Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res. 2004 Mar-Apr; 24(2C):1121-5. View in: PubMed

Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo. 2004 Mar-Apr; 18(2):107-12. View in: PubMed

Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leuk Res. 2003 Dec; 27(12):1135-42. View in: PubMed

Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol. 2003 Sep; 25(9):688-95. View in: PubMed

Preponderant mitotic activity of nonleukemic cells plays an important role in failures to detect abnormal clone in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003 Jul; 25(7):520-5. View in: PubMed

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003 May 15; 101(10):3809-17. View in: PubMed

CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003 May 01; 21(9):1798-809. View in: PubMed

Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003 May 1; 21(9):1790-7. View in: PubMed

Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003 May 01; 21(9):1790-7. View in: PubMed

Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002 Sep 15; 100(6):1957-64. View in: PubMed

Response to Donadieu and Hill "Clinical trials in childhood acute lymphoblastic leukemia: a common prognostic classification and a common induction therapy are now warranted". J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):426-8. View in: PubMed

Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002 Jul 1; 100(1):67-71. View in: PubMed

Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood. 2002 Jul 01; 100(1):67-71. View in: PubMed

Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002 Jun 15; 99(12):4257-64. View in: PubMed

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 01; 359(9321):1909-15. View in: PubMed

Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 1; 359(9321):1909-15. View in: PubMed

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002 Mar 15; 99(6):1986-94. View in: PubMed

A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):175-81. View in: PubMed

From where do clinical trials come? J Pediatr Hematol Oncol. From where do clinical trials come? J Pediatr Hematol Oncol. 2002 Mar-Apr; 24(3):172-4. View in: PubMed

Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer. 2002 Feb 15; 94(4):1102-10. View in: PubMed

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000 Dec; 14(12):2193-4. View in: PubMed

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000 Apr 06; 342(14):998-1006. View in: PubMed

Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leuk Lymphoma. 1998 Sep; 31(1-2):143-9. View in: PubMed

Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma. 1997 Nov; 27(5-6):445-57. View in: PubMed

Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study. Blood. 1997 May 15; 89(10):3769-77. View in: PubMed

Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1997 Apr 01; 89(7):2488-93. View in: PubMed

CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 1996 Dec 01; 88(11):4288-95. View in: PubMed

Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. Leuk Lymphoma. 1996 Dec; 24(1-2):57-70. View in: PubMed

Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys. 1996 Aug 01; 36(1):19-27. View in: PubMed

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24. View in: PubMed

Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood. 1995 Feb 15; 85(4):873-8. View in: PubMed

Prolonged response to carboplatin in an infant with brain stem glioma. Cancer. 1991 Jan 01; 67(1):43-7. View in: PubMed

Granulocytic sarcoma of the ileum treated by bone marrow transplantation. Am J Pediatr Hematol Oncol. 1991; 13(1):34-8. View in: PubMed

Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol. 1986 May; 4(5):744-52. View in: PubMed

Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):815-22. View in: PubMed

Powered bySC CTSI